<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>IL-1 is a key inflammatory and immune mediator in many diseases, including dry-<z:e sem="disease" ids="C0015397" disease_type="Disease or Syndrome" abbrv="">eye disease</z:e>, and its inhibition is clinically efficacious in <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> and cryopyrin-associated <z:e sem="disease" ids="C0585274" disease_type="Disease or Syndrome" abbrv="">periodic syndromes</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>To treat <z:e sem="disease" ids="C1557335" disease_type="Disease or Syndrome" abbrv="">ocular surface disease</z:e> with a topical biotherapeutic, the uniqueness of the site necessitates consideration of the agent's size, target location, binding kinetics, and thermal stability </plain></SENT>
<SENT sid="2" pm="."><plain>Here we chimerized two IL-1 receptor ligands, IL-1β and IL-1Ra, to create an optimized receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, EBI-005, for topical ocular administration </plain></SENT>
<SENT sid="3" pm="."><plain>EBI-005 binds its target, IL-1R1, 85-fold more tightly than IL-1Ra, and this increase translates to an ∼100-fold increase in potency in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>EBI-005 preserves the affinity bias of IL-1Ra for IL-1R1 over the decoy receptor (IL-1R2), and, surprisingly, is also more thermally stable than either parental molecule </plain></SENT>
<SENT sid="5" pm="."><plain>This rationally designed <z:chebi fb="68" ids="48706">antagonist</z:chebi> represents a unique approach to therapeutic design that can potentially be exploited for other β-trefoil family proteins in the IL-1 and FGF families </plain></SENT>
</text></document>